Takeda CEO Calls For A Paradigm Shift In Japanese R&D; BIO Japan Conference Takeaway Message, Head West...To China
This article was originally published in The Pink Sheet Daily
Hasegawa encouraged Japanese companies to embrace a paradigm shift in their approach to R&D, which includes being open to reverse innovation and rethinking how global R&D can be localized
You may also be interested in...
The growth in available government funding for pharmaceutical companies in China is creating a snowball of investment from domestic and multinational pharma companies more willing to overcome intellectual property concerns
TOKYO - Takeda, like most Japanese pharma, is hoping to counter the ongoing trend of patent expirations and yen appreciation by looking outward. Pushing beyond their comfort zones of Japan and U.S. markets, Japan's top pharma are pushing to gain ground in Europe and Asia. Similarly, these companies are looking outside of their own staff for expertise in these new regions
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.